Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy

Hannes Vihinen; Artturi Jokinen; Teemu D. Laajala; Nesna Wahid; Lotta Peltola; Tiia Kettunen; Aino Ronka; Leena Tiainen; Tanja Skytta; Laura Kohtamäki; Sanni Tulokas; Hanna Karhapää; Micaela Hernberg; Maria Silvoniemi; Kalle E. Mattila

doi:10.1016/j.cllc.2023.01.004

Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy

Hannes Vihinen, Artturi Jokinen, Teemu D. Laajala, Nesna Wahid, Lotta Peltola, Tiia Kettunen, Aino Ronka, Leena Tiainen, Tanja Skytta, Laura Kohtamäki, Sanni Tulokas, Hanna Karhapää, Micaela Hernberg, Maria Silvoniemi, Kalle E. Mattila

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Tidskrift	Clinical Lung Cancer
Volym	24
Nummer	4
Sidor (från-till)	295-304
Antal sidor	10
ISSN	1525-7304
DOI	https://doi.org/10.1016/j.cllc.2023.01.004
Status	Publicerad - juni 2023
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

3122 Cancersjukdomar

Åtkomst av dokument

10.1016/j.cllc.2023.01.004

1-s2.0-S1525730423000025-mainSlutlig publicerad version, 1,71 MBLicens: CC BY

Citera det här

Vihinen, H., Jokinen, A., Laajala, T. D., Wahid, N., Peltola, L., Kettunen, T., Ronka, A., Tiainen, L., Skytta, T., Kohtamäki, L., Tulokas, S., Karhapää, H., Hernberg, M., Silvoniemi, M., & Mattila, K. E. (2023). Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy. Clinical Lung Cancer, 24(4), 295-304. https://doi.org/10.1016/j.cllc.2023.01.004

@article{a013f63a94ad4e46b441150cb4a004fd,

title = "Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy",

keywords = "Antibiotics, Immune checkpoint inhibitors, Overall survival, Prognostic factor, Progression-free survival, 3122 Cancers",

author = "Hannes Vihinen and Artturi Jokinen and Laajala, {Teemu D.} and Nesna Wahid and Lotta Peltola and Tiia Kettunen and Aino Ronka and Leena Tiainen and Tanja Skytta and Laura Kohtam{\"a}ki and Sanni Tulokas and Hanna Karhap{\"a}{\"a} and Micaela Hernberg and Maria Silvoniemi and Mattila, {Kalle E.}",

year = "2023",

month = jun,

doi = "10.1016/j.cllc.2023.01.004",

language = "English",

volume = "24",

pages = "295--304",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc. ",

number = "4",

}

Vihinen, H, Jokinen, A, Laajala, TD, Wahid, N, Peltola, L, Kettunen, T, Ronka, A, Tiainen, L, Skytta, T, Kohtamäki, L , Tulokas, S , Karhapää, H, Hernberg, M, Silvoniemi, M & Mattila, KE 2023, 'Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy', Clinical Lung Cancer, vol. 24, nr. 4, s. 295-304. https://doi.org/10.1016/j.cllc.2023.01.004

TY - JOUR

T1 - Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy

AU - Vihinen, Hannes

AU - Jokinen, Artturi

AU - Laajala, Teemu D.

AU - Wahid, Nesna

AU - Peltola, Lotta

AU - Kettunen, Tiia

AU - Ronka, Aino

AU - Tiainen, Leena

AU - Skytta, Tanja

AU - Kohtamäki, Laura

AU - Tulokas, Sanni

AU - Karhapää, Hanna

AU - Hernberg, Micaela

AU - Silvoniemi, Maria

AU - Mattila, Kalle E.

PY - 2023/6

Y1 - 2023/6

KW - Antibiotics

KW - Immune checkpoint inhibitors

KW - Overall survival

KW - Prognostic factor

KW - Progression-free survival

KW - 3122 Cancers

U2 - 10.1016/j.cllc.2023.01.004

DO - 10.1016/j.cllc.2023.01.004

M3 - Article

C2 - 36774235

SN - 1525-7304

VL - 24

SP - 295

EP - 304

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 4

ER -